I-Mab (NASDAQ:NBP) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of I-Mab (NASDAQ:NBP – Free Report) from a sell rating to a hold rating in a report released on Saturday morning.

Other research analysts have also issued research reports about the company. Weiss Ratings raised I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of I-Mab in a report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.00.

Get I-Mab alerts:

Get Our Latest Research Report on NBP

I-Mab Trading Up 4.7%

NASDAQ:NBP opened at $2.00 on Friday. The firm has a 50-day moving average of $1.78. The firm has a market capitalization of $231.30 million, a P/E ratio of -5.56 and a beta of 1.47. I-Mab has a 52-week low of $1.46 and a 52-week high of $6.79.

I-Mab (NASDAQ:NBP – Get Free Report) last released its earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share (EPS) for the quarter. Research analysts anticipate that I-Mab will post -0.3 EPS for the current year.

Institutional Investors Weigh In On I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is currently owned by institutional investors and hedge funds.

I-Mab Company Profile

(Get Free Report)

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.

Read More

• Five stocks we like better than I-Mab
• 2 Biotech Stocks Shaping Up for Major Breakouts
• 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
• 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
• Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.